Psyence Group Inc. (CSE: PSYG), a leading clinical-stage life science biotechnology company specializing in the use of nature-derived psilocybin for mental health and wellbeing, is pleased to announce that its associate, Psyence Biomedical Ltd (NASDAQ: PBM), has received full approval from the Australian Health Research Ethics Committee (HREC) to initiate a Phase IIb study. The study, which will be conducted in Melbourne, Australia, aims to investigate the efficacy of nature-derived psilocybin as a treatment for Adjustment Disorder in patients recently diagnosed with cancer in the palliative care context.
According to a press release issued by PBM on March 6, 2024, a significant number of the estimated 56.8 million individuals worldwide who require palliative care each year experience a substantial burden of psychosocial distress following their cancer diagnosis. Adjustment Disorder, characterized by emotional and behavioral symptoms arising from an inability to cope with a life stressor like a cancer diagnosis, can significantly impact a patient’s quality of life and overall wellbeing.
Psyence Biomedical’s Phase IIb study, to be conducted through its subsidiary Psyence Australia (Pty) Ltd, aims to assess the therapeutic potential of nature-derived psilocybin in alleviating the symptoms of Adjustment Disorder in palliative care patients. The approval from the Australian HREC now allows the study to proceed, bringing potential hope to patients struggling with the emotional impact of their cancer diagnosis.
This groundbreaking study holds promise as psilocybin has shown potential as a novel approach to mental health treatment. Many researchers and clinicians are increasingly recognizing the therapeutic value of psilocybin in addressing various mental health conditions, including depression, anxiety, and post-traumatic stress disorder (PTSD). By initiating this Phase IIb study, Psyence Biomedical aims to explore the benefits of psilocybin specifically for Adjustment Disorder due to a recent cancer diagnosis.
With the endorsement from the Australian HREC, Psyence Biomedical is poised to pave the way for innovative and effective treatments for individuals experiencing Adjustment Disorder in the palliative care setting. This approval signifies a significant milestone for both Psyence Group and its associate, opening doors for further research and development in the field of psilocybin-based mental health therapies.
Comments